POZEN Inc. (POZN)
-NasdaqGS 5.10 
0.17(3.45%) May 24, 4:00PM EDT
| Prev Close: | 4.93 |
|---|
| Open: | 4.95 |
|---|
| Bid: | N/A |
|---|
| Ask: | 6.08 x 300 |
|---|
| 1y Target Est: | 8.13 |
|---|
| Beta: | 1.49 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 4.91 - 5.17 |
|---|
| 52wk Range: | 4.26 - 7.55 |
|---|
| Volume: | 173,273 |
|---|
| Avg Vol (3m): | 267,939 |
|---|
| Market Cap: | 154.87M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.75 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- POZEN to Present at the Jefferies 2013 Global Healthcare ConferenceBusiness Wire(Thu, May 23)
- Presence of Gastric Erosions in Patients Taking Low-Dose Aspirin for Secondary Cardiovascular Prevention May Result in a 2-Fold Increase in Future Gastric UlcersBusiness Wire(Tue, May 21)
- Socially Responsible Investing in Biotech and Pharmaceutical Companies: Expert Portfolio Manager Finny Kuruvilla Discusses His Construction Strategy with The Wall Street TranscriptWall Street Transcript(Thu, May 16)
- POZEN INC /NC FinancialsEDGAR Online Financials(Tue, May 14)
- Earnings Volatility Drives These Healthcare Stocks in a New Directionat Wall St. Cheat Sheet(Sun, May 12)
- Pozen Stock Sees Short Interest Increase 19.5%at TheStreet(Fri, May 10)
- 3 Healthcare Stock Stories Prescribed For Investorsat Wall St. Cheat Sheet(Wed, May 8)
- POZEN's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
- Pounding The Table On Pozen: Why There's Upside In This Misunderstood Nameat Seeking Alpha(Wed, May 8)
- POZEN Inc. Earnings Call scheduled for 11:00 am ET todayCCBN(Wed, May 8)
- POZEN Earnings: Everything You Must Know Nowat Wall St. Cheat Sheet(Wed, May 8)
- POZEN Reports First Quarter 2013 ResultsBusiness Wire(Wed, May 8)
- Q1 2013 POZEN Inc. Earnings Release - Before Market OpenCCBN(Wed, May 8)
- POZEN INC /NC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Wed, May 8)
- Global Opportunity for Generic Drug Players: Central and Eastern Europe, Latin America and Parts of Asia are Areas with Fertile Ground for Continued GrowthWall Street Transcript(Thu, May 2)
Key Statistics
| Forward P/E (1 yr): | 23.18 |
|---|
| P/S (ttm): | 27.34 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.26 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.20 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | -0.63 |
|---|
Business Summary
POZEN Inc., a pharmaceutical company, develops products for the treatment of acute and chronic pain, and pain related conditions in the United States. The companys products include Treximet for acute treatment of migraine attacks with or wit...
View More